A Phase 3 Study of Glofitamab With Standard Treatment in People With Previously Untreated Large B-Cell Lymphoma

Full Title

A Phase III, Multicenter, Randomized, Open Label Study Comparing the Efficacy and Safety of Glofitamab (RO7082859) in Combination with Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (POLA-R-CHP) Versus POLA-R-CHP in Previously Untreated Patients with Large B-Cell Lymphoma

Purpose

Researchers are assessing glofitamab in combination with standard treatment for people with lymphoma. The people in this study have large B-cell lymphoma that has not yet been treated. In addition, their cancer contains high levels of a protein called CD20.

Glofitamab is designed to target and kill cancer cells with CD20. It may strengthen your immune system’s ability to fight cancer cells by activating your own cells to destroy your cancer.

If you join this study, you will be randomly assigned to get one of these treatments:

• Pola-R-CHP (polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone) plus glofitamab
• Pola-R-CHP alone

Who Can Join

To join this study, there are a few conditions. You must:

• Have large B-cell lymphoma that has not yet been treated and contains high levels of CD20.
• Be able to walk and do routine activities for more than half the time you are awake.
• Be age 18-80.

Contact

For more information or to see if you can join this study, please call Dr. Gilles Salles’ office at 646-608-4153.